Munich, Germany

Ute Jaeger

USPTO Granted Patents = 7 

 

 

Average Co-Inventor Count = 3.6

ph-index = 3

Forward Citations = 43(Granted Patents)


Company Filing History:


Years Active: 2014-2020

Loading Chart...
Loading Chart...
Loading Chart...
7 patents (USPTO):Explore Patents

Title: Ute Jaeger: Innovator in Therapeutic Antibodies

Introduction

Ute Jaeger is a prominent inventor based in Munich, Germany, known for her significant contributions to the field of therapeutic antibodies. With a total of seven patents to her name, she has made remarkable strides in medical research and innovation.

Latest Patents

Among her latest patents is the invention related to nucleic acids encoding anti-Factor P antibodies. This invention focuses on antibodies or antigen-binding fragments that specifically bind to complement Factor P, which can be utilized in various therapeutic applications. Another notable patent is for the generation and profiling of fully human HuCAL GOLD-derived therapeutic antibodies specific for human CD38. This invention provides novel antibodies and methods for using recombinant antigen-binding regions that are crucial in treating hematological malignancies such as multiple myeloma.

Career Highlights

Ute Jaeger has worked with leading companies in the pharmaceutical industry, including Novartis AG and MorphoSys AG. Her work has been instrumental in advancing therapeutic solutions that address critical health issues.

Collaborations

Throughout her career, Ute has collaborated with notable professionals in her field, including Michael Tesar and Leslie Ngozi Anuna Johnson. These collaborations have further enriched her research and innovations.

Conclusion

Ute Jaeger stands out as a key figure in the development of therapeutic antibodies, with her innovative patents paving the way for advancements in medical treatments. Her contributions continue to impact the field significantly.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…